Why Moderna's Stock Is Trading Higher Today

Moderna, Inc. MRNA shares are trading higher after analysts at multiple firms raised their price targets on the stock. The company has attracted investor interest recently, as it is working on a coronavirus (COVID-19) vaccine.

Morgan Stanley maintained an Overweight rating and raised its price target from $30 to $37.

Oppenheimer maintained an Outperform rating and raised its price target from $31 to $43.

Moderna shares were trading up 10.65%, hitting a 52-week high of $38.35 on Wednesday. The stock has a 52-week low of 11.54.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsPrice TargetAnalyst Ratingswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!